{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:05:58Z","timestamp":1792037158596,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17168"],"award-info":[{"award-number":["20K17168"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K07493"],"award-info":[{"award-number":["23K07493"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020376","name":"Gout and Uric Acid Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003427","name":"Gout and Uric Acid Research Foundation of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.numecd.2024.103796","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T11:47:49Z","timestamp":1731757669000},"page":"103796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Hyperuricemia, A new cardiovascular risk"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-4347","authenticated-orcid":false,"given":"Masanari","family":"Kuwabara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hisatome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Ae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kosami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Andres-Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Lanaspa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2024.103796_bib1","first-page":"643","article-title":"[Revised version of guideline for the management of hyperuricemia and gout]","volume":"66","author":"Yamanaka","year":"2008","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.numecd.2024.103796_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1253\/circj.CJ-20-0406","article-title":"Uric acid as a risk factor for chronic kidney disease and cardiovascular disease - Japanese guideline on the management of asymptomatic hyperuricemia","volume":"85","author":"Hisatome","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2024.103796_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19724-1","article-title":"Prevalence and factors related to hypouricemia and hyperuricemia in schoolchildren: results of a large-scale cross-sectional population-based study conducted in Japan","volume":"12","author":"Aoki","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2024.103796_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000443769","article-title":"Hyperuricemia, cardiovascular disease, and hypertension","volume":"3","author":"Kuwabara","year":"2016","journal-title":"Pulse (Basel)."},{"key":"10.1016\/j.numecd.2024.103796_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41440-022-01148-z","article-title":"Tips and pitfalls in uric acid clinical research","volume":"46","author":"Kuwabara","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.numecd.2024.103796_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2024.103796_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1161\/HYPERTENSIONAHA.116.08998","article-title":"Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study","volume":"69","author":"Kuwabara","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2024.103796_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/jcp.19.5.501","article-title":"Serum uric acid levels in normal pregnancy with observations on the renal excretion of urate in pregnancy","volume":"19","author":"Boyle","year":"1966","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.numecd.2024.103796_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ard.28.4.366","article-title":"Studies of uric acid pool size and turnover rate","volume":"28","author":"Scott","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.numecd.2024.103796_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.numecd.2024.103796_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.10792","article-title":"Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.numecd.2024.103796_bib12","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/jama.2016.3517","article-title":"Trends in gout and rheumatoid arthritis hospitalizations in the United States, 1993-2011","volume":"315","author":"Lim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.103796_bib13","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/annrheumdis-2021-220439","article-title":"Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan","volume":"80","author":"Koto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.numecd.2024.103796_bib14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103796_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2024.103796_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41440-023-01273-3","article-title":"Update in uric acid, hypertension, and cardiovascular diseases","author":"Kuwabara","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.numecd.2024.103796_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.117.10370","article-title":"Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study","volume":"71","author":"Kuwabara","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2024.103796_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040942","article-title":"The optimal range of serum uric acid for cardiometabolic diseases: a 5-year Japanese cohort study","volume":"9","author":"Kuwabara","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2024.103796_bib19","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/HYPERTENSIONAHA.122.17956","article-title":"Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk","volume":"79","author":"Borghi","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2024.103796_bib20","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103796_bib21","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41440-023-01273-3","article-title":"Update in uric acid, hypertension, and cardiovascular diseases","volume":"46","author":"Kuwabara","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.numecd.2024.103796_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/HYPERTENSIONAHA.120.16547","article-title":"Urate, blood pressure, and cardiovascular disease: evidence from mendelian randomization and meta-analysis of clinical trials","volume":"77","author":"Gill","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2024.103796_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-024-02138-y","article-title":"Cardiovascular outcomes of uric acid lowering medications: a meta-analysis","author":"Jamil","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.numecd.2024.103796_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.numecd.2024.103796_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjcard.2021.05.007","article-title":"Relation of serum uric acid and cardiovascular events in Young adults aged 20-49 years","volume":"152","author":"Seki","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib26","article-title":"Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: a nationwide cohort study from Japan","volume":"9","author":"Akashi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.numecd.2024.103796_bib27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1253\/circj.CJ-08-0828","article-title":"Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study","volume":"73","author":"Okura","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2024.103796_bib28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/HJH.0000000000003319","article-title":"Serum uric acid\/serum creatinine ratio as a predictor of cardiovascular events. Detection of prognostic cardiovascular cut-off values","volume":"41","author":"Casiglia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2024.103796_bib29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/HJH.0000000000003068","article-title":"The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study","volume":"40","author":"Ungar","year":"2022","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2024.103796_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae222","article-title":"Associations of uric acid with the risk of cardiovascular disease and all-cause mortality among individuals with chronic kidney disease: the Kailuan Study","author":"Li","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1161\/HYPERTENSIONAHA.121.17555","article-title":"Serum urate trajectory in Young adulthood and incident cardiovascular disease events by middle age: CARDIA study","volume":"78","author":"Morikawa","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2024.103796_bib32","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial","volume":"375","author":"Noman","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.103796_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.numecd.2024.103796_bib34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the gfr decline in patients with ckd and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2024.103796_bib35","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and CaRdiorenovascular events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103796_bib36","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cpt.3217","article-title":"Impacts of febuxostat on cerebral and cardiovascular events in elderly patients with hyperuricemia: post hoc analysis of a randomized controlled trial","volume":"115","author":"Sugawara","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2024.103796_bib37","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.103796_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2012.04.011","article-title":"Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities","volume":"164","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2024.103796_bib39","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.103796_bib40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/CIRCULATIONAHA.118.037976","article-title":"Letter by Kuwabara regarding article, \"assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study\"","volume":"139","author":"Kuwabara","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103796_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2024.103796_bib42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2024.103796_bib43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11739-019-02070-y","article-title":"Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients","volume":"14","author":"Cicero","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.numecd.2024.103796_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","article-title":"Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia","volume":"8","author":"Nakagomi","year":"2015","journal-title":"IJC Metabolic & Endocrine"},{"key":"10.1016\/j.numecd.2024.103796_bib45","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehz154","article-title":"Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data","volume":"40","author":"Singh","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103796_bib46","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/eurheartj\/ehaa179","article-title":"Febuxostat and atrial fibrillation","volume":"41","author":"Kuwabara","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103796_bib47","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1093\/eurheartj\/ehab619","article-title":"Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout","volume":"42","author":"Kang","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2024.103796_bib48","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/art.40914","article-title":"Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al","volume":"71","author":"Bubb","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.numecd.2024.103796_bib49","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41066","article-title":"Xanthine Oxidase Inhibitor Withdrawal Syndrome? Comment on the Article by Choi et al","volume":"71","author":"Johnson","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.numecd.2024.103796_bib50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.numecd.2024.103796_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fphar.2019.00098","article-title":"Shortage of cellular ATP as a cause of diseases and strategies to enhance ATP","volume":"10","author":"Johnson","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.numecd.2024.103796_bib52","article-title":"Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome","volume":"14","author":"Kuwabara","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.numecd.2024.103796_bib53","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","article-title":"Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout","volume":"4","author":"Klauser","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/acr.25312","article-title":"Frequently encountered artifacts in the application of dual-energy computed tomography to cardiovascular imaging for urate crystals in gout: a matched-control study","volume":"76","author":"Yokose","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.numecd.2024.103796_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1433227","article-title":"Imaging human coronary cholesterol\/urate crystals with cross-polarized micro-optical coherence tomography","volume":"11","author":"Nishimiya","year":"2024","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10.1016\/j.numecd.2024.103796_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2010.05.002","article-title":"Hyperuricemia predicts adverse outcomes in patients with heart failure","volume":"151","author":"Hamaguchi","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib57","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.CIR.0000065637.10517.A0","article-title":"Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging","volume":"107","author":"Anker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103796_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.04.007","article-title":"Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study)","volume":"96","author":"Kojima","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.numecd.2024.103796_bib60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1186\/s12872-023-03544-w","article-title":"Serum uric acid and outcome in hospitalized elderly patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes","volume":"23","author":"Yan","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.numecd.2024.103796_bib61","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: a population-based cohort study","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103796_bib62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/heart.87.3.229","article-title":"Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study","volume":"87","author":"Struthers","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2024.103796_bib63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.numecd.2024.103796_bib64","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib65","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103796_bib66","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/hc4501.098928","article-title":"Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy","volume":"104","author":"Cappola","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2024.103796_bib67","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/hrt.2004.040477","article-title":"Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure","volume":"91","author":"Gavin","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2024.103796_bib68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cardfail.2006.05.005","article-title":"The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study","volume":"12","author":"Cingolani","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.numecd.2024.103796_bib69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1536\/ihj.17-560","article-title":"Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF)","volume":"59","author":"Yokota","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.numecd.2024.103796_bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/HJH.0000000000003564","article-title":"Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies","volume":"42","author":"Gherbesi","year":"2024","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2024.103796_bib71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2016.11.268","article-title":"Hyperuricemia is an independent competing risk factor for atrial fibrillation","volume":"231","author":"Kuwabara","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2024.103796_bib72","article-title":"Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis","volume":"2022","author":"Gao","year":"2022","journal-title":"Internet J Endocrinol"},{"key":"10.1016\/j.numecd.2024.103796_bib73","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/europace\/euu198","article-title":"Usefulness of serum uric acid level to predict atrial fibrillation recurrence after cryoballoon-based catheter ablation","volume":"16","author":"Canpolat","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.numecd.2024.103796_bib74","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1253\/circj.CJ-18-0508","article-title":"Uric acid level and new-onset atrial fibrillation in the Japanese general population - longitudinal study","volume":"83","author":"Kawasoe","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2024.103796_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1253\/circj.CJ-18-1233","article-title":"Gender difference in the association between uric acid and atrial fibrillation","volume":"83","author":"Kuwabara","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.numecd.2024.103796_bib76","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2014070660","article-title":"Uric acid and cardiovascular events: a mendelian randomization study","volume":"26","author":"Kleber","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324004307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475324004307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:37:22Z","timestamp":1762331842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475324004307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0939475324004307"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.103796","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperuricemia, A new cardiovascular risk","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.103796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103796"}}